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We synthesized a series of novel amide derivatives of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic
acid and assessed their antiproliferative activities against three human cancer cell lines (Huh7, human
liver; MCF7, breast and HCT116, colon carcinoma cell lines) with the sulforhodamine B assay. Compound
4j with 2-chloro-4-pyridinyl group in the amide part exhibited promising cytotoxic activity against all
cell lines with IC50 values of 1.6 mM, 3.3 mM and 1.1 mM for Huh7, MCF7 and HCT116 cells, respectively,
and produced dramatic cell cycle arrest at SubG1/G1 phase as an indicator of apoptotic cell death in-
duction. On the basis of their high potency in cellular environment, these straightforward pyrazole-3-
carboxamide derivatives may possess potential in the design of more potent compounds for interven-
tion with cancer cell proliferation.
© 2014 Elsevier Masson SAS. All rights reserved.1. Introduction
Pyrazole and its derivatives have been widely studied for
development of new therapeutics for various diseases including
cancer [1,2]. In the last decade, many researchers have reported a
large series of pyrazole derivatives having promising anticancer
activities [3e11], indicating the use of pyrazole motif as a powerful
tool for novel anticancer drug development. Many reports indi-
cated that highly potent and efficient anticancer activity was
observable when one of the aryl rings in diarylpyrazole core was
substituted by other heterocycles possessing nitrogen and/or sulfur
[2]. Among the reported studies, 4-quinolinylpyrazoles, 4-
quinolinylimidazoles, 4-quinoxalinylpyrazoles and 4-([1,2,4]tri-
azolo[1,5-a]pyridin-6-yl)pyrazoles showed promising anti-
proliferative properties by inhibiting transforming growth factor-b
type 1 receptor kinase, also known as activin receptor-like kinase 5
(ALK5) [12e15]. Moreover, pyrazole-5-carboxylate [10,16], pyr-
azole-5-carboxamide [4] and pyrazole-5-carbohydrazide [6,8,9,11]
derivatives were also shown to have a significant anticancergazi.edu.tr (E. Banoglu).
served.activity against A549 lung cancer cell lines by inducing apoptosis or
autophagy. Therefore, a wide range of information provided in the
literature presents an ample opportunity for further investigation
of pyrazole derivatives for the discovery of novel anticancer ther-
apeutics. Hence, inspired by the promising results of current
research on anticancer pyrazole derivatives, we have designed and
synthesized a number of novel 5-(p-tolyl)-1-(quinolin-2-yl)-1H-
pyrazole-3-carboxylic acid amides in rationale to previously re-
ported potent ALK5 inhibitors and evaluated the effects of these
compounds for their antiproliferative potential against different
cancer cell lines using sulforhodamine B (SRB) assay. The target
compounds 4aeo were designed by replacing the 3,4-
diarylpyrazole motif in ALK5 inhibitors with 1,5-diarylpyrazole
while having a quinolin-2-yl substitution at C(5) of pyrazole with
subsequent modifications at C(3)-carboxamide chain to examine
their effect on the biological activity (Fig. 1).2. Results and discussion
2.1. Chemistry
The 1-(quinolin-2-yl)-5-(4-methylphenyl)pyrazol-3-carboxa
mides (4aeo) studied in this communication were synthesized
Fig. 1. Several ALK5 inhibitors with antiproliferative activities (1e3) under develop-
ment, and the general structure of the synthesized compounds (4).
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mated flash chromatography and checked for purity by
elemental analysis and UPLC before being tested in biological
assays (purity was >97%). The structures of these compounds
were confirmed by high-resolution mass spectrometry (HRMS),
elemental analysis, IR, 13C NMR and 1H NMR spectral data. As
shown in Scheme 1, the synthesis of methyl 4-(4-methylphenyl)-
2,4-dioxobutanoate (1) was carried out by Claisen condensation
of the commercially available acetophenone with dimethyl oxa-
late in the presence of a strong base [17]. The methyl ester of the
1-(quinolin-2-yl)-5-(4-methylphenyl)pyrazole-3-carboxylic acid
was then conveniently synthesized by condensation of the diketo
ester (1) with 2-hydrazinylquinoline (2) in methanol in the
presence of 0.5 eq HCl, which was subsequently hydrolyzed to
free carboxylic acid (3) as described previously [18]. The final
amide derivatives were produced either by reaction of the acylScheme 1. Synthesis of amide derivatives of 5-(4-methylphenyl)-1-(quinolin-2-yl)-1H-py
hydrate, EtOH, reflux, 8 h; iii. a) MeOH, HCl, reflux, 10 h; b) LiOH, THF:H2O (1:1), 70 C, 3 h; i
CH2Cl2, rt for 4jem.chloride of 3 with appropriate amines (4jem) or by using N-
ethyl-N0-(3-dimethylaminopropyl)carbodiimide hydrochloride
(EDC) as the carboxyl group activator (4aei, 4neo). Therefore,
we aimed to trace a tentative structureeactivity relationship
(SAR) profile for potential antiproliferative agents by modifica-
tion of the carboxyl side chain of the starting intermediate 3
through amidation with various amines of different size, basicity
and hydrophobicity.2.2. Biological evaluation
In order to determine the potential anticancer activity of the
obtained pyrazole carboxamides (4aeo), we evaluated their cyto-
toxic activity on three different cancer cell lines including human
liver (Huh7), breast (MCF7) and colon (HCT116) carcinoma cells by
SRB assay for determining the IC50 values [19]. The compounds
were bioactive in all three of the cancer cell lines with IC50 values in
micromolar ranges (Table 1). In this study, Camptothecin (CPT) was
included as an experimental positive control. The cytotoxic activ-
ities of 4ceh, 4keo having various substituents such as bromine,
chlorine, trifluoromethyl, methoxy and nitrile in the pyridine ring
were compared with that of the unsubstituted pyridine derivatives
4aeb and 4iej as discussed below.
All amide derivatives (4aeo) inhibited cell proliferation with
IC50 values in the range of 1.1e79.5 mM as shown in Table 1. The
compound 4j bearing 2-chloro-4-pyridinyl group in the amide part
of 1,5-diarypyrazole-3-carboxamide core displayed the most
potent growth inhibitory activity against all cell lines (IC50 ¼ 1.6 mM
for Huh7, 3.3 mM for MCF7, and 1.1 mM for HCT116 cells). When
there is no substitution (4i) or 3-bromo substitution (4k) at 4-
pyridinyl, the cytotoxicity was significantly decreased on all cell
lines with IC50 values between 8 mM and 15.5 mM (Table 1).
Furthermore, when a methylene linker was inserted between the
pyridine ring and carboxamide part disrupting the conjugation
(4o), the cytotoxic activity again decreased with IC50 values of
11.2e19.0 mM for all cell lines. Compound 4n having 2-methoxy-3-
pyridinyl substituent demonstrated much better cytotoxic activity
against Huh7 cells (IC50 ¼ 7.9 mM) as compared to MCF7 andrazole-3-carboxylic acid. Reagents and conditions: i. NaOCH3, MeOH, rt; ii. Hydrazin
v. Amine derivatives, EDC, DMAP, CH2Cl2, rt for 4aei and 4neo or oxalyl chloride, DIEA,
Table 1
IC50 values in mM concentrations for 4aeo with 72 h of treatment.a
Cmpd. No R Huh7 MCF7 HCT116
4a (pyridin-4-yl)piperazine 7.8 ± 0.5 4.7 ± 0.5 7.1 ± 1.0
4b (pyridin-2-yl)piperazine 4.8 ± 2.0 12.0 ± 1.3 5.1 ± 1.1
4c (3-CF3-pyridin-2-yl)piperazine 12.7 ± 0.2 5.8 ± 0.5 9.7 ± 1.7
4d (6-CF3-pyridin-2-yl)piperazine 10.2 ± 2.2 11.4 ± 1.5 9.4 ± 2.5
4e (5-CF3-pyridin-2-yl)piperazine 20.9 ± 7.0 44.7 ± 24 17.0 ± 2.2
4f (3-Cl-5-CF3-pyridin-2-yl)
piperazine
8.0 ± 1.8 48.0 ± 7.5 13.3 ± 1.1
4g (3-CN-pyridin-2-yl)piperazine 21.5 ± 2.2 79.5 ± 25 39.4 ± 3.0
4h (3,5-diCl-pyridin-4-yl)piperazine 4.6 ± 1.9 9.7 ± 0.3 4.8 ± 1.0
4i pyridin-4-yl 8.0 ± 1.9 15.4 ± 0.6 8.1 ± 2.2
4j 2-Cl-pyridin-4-yl 1.6 ± 0.2 3.3 ± 0.9 1.1 ± 1.0
4k 3-Br-pyridin-4-yl 13.1 ± 0.1 11.0 ± 1.7 15.5 ± 0.6
4l 3,5-diBr-pyridin-2-yl 11.5 ± 0.2 16.9 ± 2.5 9.6 ± 0.6
4m 2,6-diCl-pyridin-3-yl 14.0 ± 0.8 12.7 ± 0.05 7.9 ± 1.5
4n 2-OCH3-pyridin-3-yl 7.9 ± 2.3 30.2 ± 8 15.7 ± 2.1
4o pyridin-3-ylmethyl 14.1 ± 1.0 19.0 ± 0.7 11.2 ± 0.8
CPT 0.004 0.0006 0.00015
a IC50 values were calculated from the cell growth inhibition percentages ob-
tained with five different concentrations and data obtained were expressed as
means of ±SD.
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while, derivatives having 2,6-dichloro-3-pyridinyl (4m) and 3,5-
dibromo-2-pyridinyl (4l) in the carboxamide part showed prefer-
able activity for HCT116 (IC50 ¼ 7.9 and 9.6 mM, respectively) with
regard to Huh7 and MCF7 cells (Table 1).
For carboxamides having (pyridinyl)piperazine side chain, the
(pyridin-4-yl)piperazine (4a), (pyridin-2-yl)piperazine (4b) and
(3,5-dichloropyridin-4-yl)piperazine (4h) derivatives were the
most active ones for their cytotoxic activity with differentially se-
lective IC50 values with less than 5 mM in some cell lines. For
instance, MCF7 cells were found more sensitive to 4a
(IC50 ¼ 4.7 mM) while the Huh7 and HCT116 cells were more sen-
sitive towards 4b and 4h (IC50 of 4.8 and 5.1 mM for 4b; 4.6 and
4.8 mM for 4h, respectively). We also investigated the effect of CF3
substituent on (pyridine-2-yl)piperazines. The (3-CF3-pyridin-2-yl)
piperazine (4c) resulted in a better cytotoxicity against MCF7 cells
(IC50 of 5.8 mM), while 6-CF3-pyridin-2-yl derivative (4d) was
equally active against all cell lines with IC50 values in the range of
9.4e11.4 mM. However, a diminished activity was observable with
5-CF3-pyridin-2-yl derivative (4e IC50 ¼ 17e44.7 mM). Moreover,
inclusion of chlorine at 3 position of pyridine ring in 4e producing
4f improved the cytotoxic activity towards Huh7 cells (8.0 mM vs.
20.9 mM). 3-Cyanopyridin-2-yl (4g) derivative was the least active
molecule within the (pyridine-2-yl)piperazine series (IC50 values of
21.5e79.5 mM).
Recent studies have shown several diarylpyrazole derivatives
resembling the general structure of present work possess ALK5,
FLT3, ERK and B-raf kinase inhibitory activities suggesting that the
kinase inhibition may play a role for the observed cytotoxicity of
present compounds [12e15,20,21]. Therefore, in order to investi-
gate the mechanism of action, and the kinase inhibitory profile of
this new class of compounds, compound 4j with the highest po-
tency on all cancer cell lines was tested at a single dose concen-
tration of 10 mM over a panel of 140 kinases (Table S1, Supporting
Material) using a radioactive (33P-ATP) filter-binding assay atInternational Center for Kinase Profiling (University of Dundee,
Scotland). As shown in Table S1, compound 4j has shown small
inhibitory potency for some of kinases in the series with an inhi-
bition percentage of 20e30% at the testing dose. The insignificant
potency of 4j over a panel of kinase enzymes cannot justify for its
strong and broad spectrum anticancer activity, and this suggests
the presence of other underlying mechanisms that control the ac-
tivity of this new compound against cancer cells. We also analyzed
the effect of 4j (10 mM) on tubulin polymerization, and again, no
inhibitory effect on tubulin polymerization was observed (data not
shown).2.2.1. Effects of the 4a, 4j and 4o on the morphology of Huh7 cells
A series of selected active compounds (4a, 4j and 4o) were
examined to determine whether the decrease in cell viability/
number was caused by apoptosis. First, the effect of selected
compounds was analyzed on their cell morphology with light mi-
croscopy. Human liver cancer cells (Huh7) were treated with 4a, 4j
and 4o at their IC50 values obtained upon 72 h of incubation
(Table 1) in comparison with DMSO controls. As shown in Fig. 2(A)
under invertedmicroscopy, all three compounds induced cell death
with various morphologies including formation of intracytoplasmic
vacuoles to indicatewhether the observed cell death was caused by
the induction of autophagy. It is also known that a cell that is un-
dergoing apoptosis demonstrates nuclear condensation and DNA
fragmentation, which can be detected by staining with Hoechst
33258 and fluorescence microscopy. In treatment of Huh7 cells
with each compound at IC50 concentrations, we observed an
apparent morphological change, such as nuclear condensation and
fragmentation in the cells (Fig. 2(B)), which was in parallel with
their cell cycle analysis (see below Fig. 3).2.2.2. Effects of 4a, 4j and 4o on cell cycle arrest in Huh-7 and
Mahlavu HCC cells
Intervention with deregulated cell cycle progression in cancer
cells correlates well with the inhibition of cell proliferation and
apoptosis, and targeting the cell cycle has been a growing area as a
new approach for cancer therapy [22,23]. Indeed, 4a, 4j and 4o
induced a dose-dependent inhibition of cell growth implying that
these compounds may affect the cell cycle. As shown in Fig. 3,
changes of the cell cycle profile induced by 4a, 4j and 4o were
studied using flow cytometry. Cells were harvested on 48 h after
compound treatment at their IC50 concentrations and analyzed for
the distribution of subG1, G0/G1, S and G2/M phases of the cell
cycle. Normally, healthy well-differentiated HCC cell lines would be
60e70% in G1 phase, 20% in S phase, and 20% in G2-M phase. Our
results revealed that compound 4j showed dramatic cell cycle ar-
rest in SubG1/G1 phase in Huh7 and Mahlavu cell lines, which is an
indicator of apoptotic cell death induction. On the other hand,
compound 4a also causedminor cell cycle arrest at SubG1/G1 phase
in Mahlavu cell line. SubG1/G1 cell cycle arrest is not only reported
with apoptosis but also reported to be associated with autophagy
[24]. To determine if the compounds were involved in autophagic
processes, western blot analysis of the classical autophagosome
marker, microtubule-associated protein light chain 3 (LC3), in Huh7
cells was done. During autophagy LC3 is cleaved to its cytosolic
form LC3-1. Lipidation leads to the LC3-2 form, which becomes
associated with the autophagosomes. Conversion of LC3-1 to LC3-2
is therefore a marker for the autophagosome formation [25]. As
shown in Fig. 4, LC3-2 levels by 72 h increased significantly for 4a
and 4o, while therewas no LC3-1 to LC3-2 conversionwith 4j. Since
the Western blot results indicated autophagy induction by 4a and
4o, together we suggest that 4a and 4o's cytotoxic bioactivities may
involve combined actions of autophagy and apoptosis.
Fig. 2. A) Live images of human liver cancer (Huh7) cells treated with compounds 4a, 4j, 4o and DMSO control for 72 h and visualized under inverted microscope (20). B)
Fluorescent nuclear staining (40) of liver cancer (Huh7) cells plated on coverslips and treated with compounds 4a, 4j, 4o at IC50 concentrations or DMSO control for 72 h. Nuclear
Hoechst 33258 stain (Sigma) was used to stain the cells.
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In this communication, a series of 1-(quinolin-2-yl)-5-(4-
methylphenyl)pyrazole-3-carboxylic acid amides has been syn-
thesized and evaluated for their antiproliferative activities against
three selected human cancer cell lines. The preliminary SAR in this
series of compounds have been established and discussed. The
compound 4j had the lowest IC50 concentration in all cell lines(IC50 ¼ 1.1e3.3 mM) by inducing apoptosis with significant cell cycle
arrest at SubG1/G1 phase in Mahlavu and Huh7 cell lines. In
addition, compound 4a with considerable IC50 values against all
cells (4.7e7.8 mM) significantly induced autophagy in Huh7 cells.
Therefore, these results simply imply that compounds 4a and 4j
could be good lead candidates for further development, and slight
structural modifications of these derivatives may yield prospective
anticancer agents for breast, liver and colon cancer cells.
Fig. 3. FACS-mediated cell-cycle analysis of Huh7 and Mahlavu liver cancer cells, which were treated with either DMSO or compounds 4a, 4j, 4o at IC50 concentrations for 48 h. The
area parameter histogram was used to determine the percentage of cells in SubG1, G1, S and G2/M phases (A) and the graph showing the percentage of cells in each phase (B).
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Fig. 4. Western blot analysis of LC3-1 to LC3-2 conversion in human liver (Huh7) cancer cells treated with the compounds 4a, 4j, 4o or DMSO control for 72 h.
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4.1. Chemistry
1H and 13C NMR spectra were recorded in CDCl3 or DMSO-d6 on
a Varian Mercury 400 MHz High Performance Digital FT-NMR
spectrometer using tetramethylsilane as the internal standard at
the NMR facility of Faculty of Pharmacy, Ankara University. All
chemical shifts were recorded as d (ppm). High-resolution mass
spectra data (HRMS) were collected in-house using a Waters LCT
Premier XE Mass Spectrometer (high sensitivity orthogonal accel-
eration time-of-flight instrument) operating in ESI (þ) method, also
coupled to an AQUITY Ultra Performance Liquid Chromatography
system (Waters Corporation, Milford, MA, USA). Melting points
were determined with an SMP-II Digital Melting Point Apparatus
(Schorpp Geaetetechnik, Germany), and are uncorrected. IR spectra
were obtained using a Perkin Elmer Spectrum 400 FTIR/FTNIR
spectrometer equipped with a Universal ATR Sampling Accessory
and only carbonyl stretching frequencies were given. Flash chro-
matography was performed with a Combiflash®Rf automated flash
chromatography system with RediSep columns (Teledyne-Isco,
Lincoln, NE, USA) using hexaneeethyl acetate, dichlor-
omethaneeethyl acetate and dichloromethaneemethanol solvent
gradients. The purity of the final compounds was determined to be
>97% by UPLC with UV detector and elemental analysis (LECO 932
CHNS analyzer, Leco Corporation, St. Joseph, MI). Elemental ana-
lyses indicated by the symbols of the elements were within ±0.4%
of the theoretical values. Methyl 4-(4-methylphenyl)-2,4-
dioxobutanoate (1) was obtained by the reaction of 40-methyl-
acetophenone with dimethyloxalate as described previously [17].
2-Hydrazinoquinoline (2) was synthesized by the reaction of 2-
chloroquinoline with hydrazine hydrate [26].
4.1.1. 5-(4-Methylphenyl)-1-quinolin-2-yl-1H-pyrazol-3-carboxylic
acid (3)
To a mixture of methyl 4-(4-methylphenyl)-2,4-dioxobutanoate
(1) (5.44 mmol) in methanol (15 ml), 2-hydrazinoquinoline (2)
(5.71 mmol) and concentrated HCl (2.72 mmol) were added and
heated at reflux temperature for 10 h. The resulting solution was
cooled, the precipitate was collected by filtration and recrystallized
from methanol to produce methyl 5-(4-methylphenyl)-1-quinolin-
2-yl-1H-pyrazol-3-carboxylate (3a) in 90% yield; Mp 152e153 C.
IR (ATR): 1717 cm1. 1H NMR (CDCl3): d 2.34 (3H, s), 3.98 (3H, s),
7.06 (1H, s), 7.10 (2H, d, J¼ 8.0 Hz), 7.20 (2H, d, J¼ 8.4 Hz), 7.54e7.57
(1H, m), 7.66e7.70 (2H, m), 7.81e7.84 (2H, m), 8.22 (1H, d,
J ¼ 8.4 Hz). 13C NMR (CDCl3): d 21.56, 52.49, 111.02, 117.63, 127.46,
127.65, 127.74, 129.11, 129.19, 129.55, 130.55, 138.89, 138.98, 144.91,
146.05, 146.62, 150.86, 163.02. HRMS (m/z): [MþH]þ calcd forC21H18N3O2: 344.1399; found: 344.1400. Anal. Calcd for
C21H17N3O2: C, 73.45; H, 4.99; N, 12.24; found C, 73.42; H, 4.92; N,
12.23.
The obtained ester derivative (5 mmol) was subsequently hy-
drolyzed to corresponding acid (3) in THF/water (1:1) with
LiOH$H2O (15 mmol) by heating at 70 C for 3 h. The reaction
mixture was poured into water and acidified with 6 N HCl, pre-
cipitatewas collected by filtration andwashedwithwater, and used
in the synthesis of amide derivatives. Yield 99%; Mp 228 C. IR
(ATR): 1719 cm1. 1H NMR (CDCl3): d 2.36 (3H, s), 7.11 (1H, s), 7.12
(2H, d, J ¼ 8.0 Hz), 7.22 (2H, d, J ¼ 8.4 Hz), 7.56e7.60 (1H, m),
7.68e7.72 (2H, m), 7.82e7.86 (2H, m), 8.25 (1H, d, J¼ 8.8 Hz). HRMS
(m/z): [MþH]þ calcd for C20H16N3O2: 330.1243; found: 330.1226.
4.1.2. General synthesis of amide derivatives
4.1.2.1. Method A. To a mixture of the carboxylic acid derivative 3
(1 mmol) in 10 ml CH2Cl2, the appropriate amine (1.1 mmol), 4-
dimethylaminopyridine (DMAP) (0.2 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (1.1 mmol) were
added, and stirred at room temperature overnight. The reaction
mixture was diluted with CH2Cl2 and washed with 1 N HCl
(3  20 ml), 5% NaHCO3 (3  20 ml), and brine. After drying over
Na2SO4, solvent was evaporated under reduced pressure and the
crude product was purified by flash chromatography.
4.1.2.2. Method B. To the solution of 3 (1 mmol) in CH2Cl2 (20 ml),
oxalyl chloride (1.5 mmol) and catalytic amount of DMF (three
drops) were added at 0 C, and stirred for 30 min. After completion
of the reaction, the mixture was concentrated to remove excess of
oxalyl chloride. To the solution of acid chloride in fresh CH2Cl2
(25 ml), N,N-diisopropylethylamine (DIEA) (2 mmol) was added
followed by amine (1.1 mmol) at 0 C and allowed to stir at RT. After
completion of the reaction, reaction mixture was washed with
water (3  30 ml) and brine (3  30 ml), and then the combined
organic layer was dried over Na2SO4 and then evaporated to dry-
ness and the crude product was purified by flash chromatography.
4.1.3. 2-[5-(4-Methylphenyl)-3-[4-(pyridin-4-yl)piperazine-1-
carbonyl]-1H-pyrazol-1-yl]quinoline (4a)
Prepared from 3 (1.2 mmol) and 1-(pyridin-4-yl)piperazine
(1.3 mmol) using method A. Flash chromatography CH2Cl2:MeOH;
yield 70%; Mp 200 C. IR (ATR): 1634 cm1. 1H NMR (CDCl3): d 2.36
(3H, s), 3.46e3.49 (4H, m), 3.99 (2H, bt), 4.36 (2H, bt), 6.68 (2H, d,
J ¼ 6.0 Hz), 6.98 (1H, s), 7.12 (2H, d, J ¼ 8.4 Hz), 7.23 (2H, d,
J¼ 8.0 Hz), 7.56e7.61 (2H, m), 7.69e7.73 (1H, m), 7.82e7.86 (2H, m),
8.23 (1H, d, J ¼ 8.4 Hz), 8.30e8.32 (2H, m). HRMS (m/z): [MþH]þ
calcd for C29H27N6O: 475.2246; found: 475.2234.
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carbonyl]-1H-pyrazol-1-yl]quinoline (4b)
Prepared from 3 (1.2 mmol) and 1-(2-pyridyl)piperazine
(1.3 mmol) using method A. Flash chromatography CH2Cl2:EtOAc;
yield 86%; Mp 141e142 C. IR (ATR): 1614 cm1. 1H NMR (CDCl3):
d 2.37 (3H, s), 3.68 (4H, bt), 3.97 (2H, bt), 4.29 (2H, bt), 6.65e6.69
(2H, m), 6.95 (1H, s), 7.12 (2H, d, J ¼ 8.0 Hz), 7.24 (2H, d, J ¼ 8.4 Hz),
7.51e7.58 (2H, m), 7.66 (1H, d, J ¼ 8.8 Hz), 7.69e7.71 (1H, m), 7.78
(1H, d, J ¼ 8.4 Hz), 7.84 (1H, d, J ¼ 8.0 Hz), 8.21e8.24 (2H, m). 13C
NMR (CDCl3): d 21.31, 42.32, 45.15, 45.75, 46.81, 107.19, 111.23,
113.74, 117.04, 127.00, 127.21, 127.46, 127.60, 128.82, 128.93, 129.13,
130.25, 137.61, 138.43, 138.61, 145.12, 146.33, 148.02, 148.10, 150.84,
159.22, 162,62. HRMS (m/z): [MþH]þ calcd for C29H27N6O:
475.2243; found: 475.2246. Anal. Calcd for C29H26N6O: C, 73.40; H,
5.52; N, 17.71; found C, 73.61; H, 5.65; N, 17.84.
4.1.5. 2-[5-(4-Methylphenyl)-3-{4-[3-(trifluoromethyl)pyridin-2-
yl]piperazine-1-carbonyl}-1H-pyrazol-1-yl]quinoline (4c)
Prepared from 3 (1.2 mmol) and 1-[3-(trifluoromethyl)-2-
pyridinyl]piperazine (1.3 mmol) using method A. Flash chroma-
tography CH2Cl2:EtOAc; yield 70%; Mp 111 C. IR (ATR): 1624 cm1.
1H NMR (CDCl3): d 2.36 (3H, s), 3.36e3.42 (4H, m), 3.99 (2H, bt),
4.27 (2H, bt), 6.93 (1H, s), 7.04 (1H, dd, J ¼ 7.6 and 4.8 Hz), 7.12 (2H,
d, J ¼ 8.4 Hz), 7.24 (2H, d, J ¼ 8.4 Hz), 7.53e7.57 (1H, m), 7.66e7.70
(2H, m), 7.78 (1H, d, J¼ 8.4 Hz), 7.83 (1H, d, J¼ 8.4 Hz), 7.90 (1H, dd,
J ¼ 7.6 and 1.6 Hz), 8.22 (1H, d, J ¼ 8.4 Hz), 8.46 (1H, dd, J ¼ 4.8 and
1.6 Hz). 13C NMR (CDCl3): d 21.30, 42.54, 47.21, 50.64, 51.26, 111.13,
117.08, 117.35, (2JCeF ¼ 31 Hz), 117.46, 123.87 (1JCeF ¼ 271 Hz),
126.96, 127.21, 127.44, 127.64, 128.81, 128.94, 129.13, 130.21, 137.27
(3JCeF ¼ 5 Hz), 138.39, 138.60, 145.08, 146.32, 148.15, 150.86, 151.09,
159.50, 162.72. HRMS (m/z): [MþH]þ calcd for C30H26F3N6O:
543.2120; found: 543.2145. Anal. Calcd for C30H25F3N6O: C, 66.41;
H, 4.64; N, 15.49; found C, 66.82; H, 4.78; N, 15.68.
4.1.6. 2-[5-(4-Methylphenyl)-3-{4-[6-(trifluoromethyl)pyridin-2-
yl]piperazine-1-carbonyl}-1H-pyrazol-1-yl]quinoline (4d)
Prepared from 3 (1.2 mmol) and 1-[6-(trifluoromethyl)pyridin-
2-yl]piperazine (1.3 mmol) using method A. Flash chromatography
CH2Cl2:EtOAc; yield 79%; Mp 177 C. IR (ATR): 1616 cm1. 1H NMR
(CDCl3): d 2.37 (3H, s), 3.72e3.78 (4H, m), 3.97 (2H, bt), 4.32 (2H,
bt), 6.81 (1H, d, J ¼ 8.8 Hz), 6.97 (1H, s), 6.99 (1H, d, J ¼ 7.2 Hz), 7.12
(2H, d, J ¼ 8.0 Hz), 7.24 (2H, d, J ¼ 8.4 Hz), 7.55e7.65 (3H, m),
7.68e7.72 (1H, m), 7.80e7.86 (2H, m), 8.24 (1H, d, J ¼ 8.8 Hz). 13C
NMR (CDCl3): d 21.30, 42.19, 44.72, 45.17, 46.61, 109.34
(3JCeF ¼ 3 Hz), 109.55, 111.31, 117.07, 121.54 (1JCeF ¼ 272 Hz), 127.04,
127.24, 127.47, 127.52, 128.85, 128.92, 129.16, 130.28, 138.49, 138.65,
145.15, 146.37, 146.46 (2JCeF ¼ 34 Hz), 148.02, 150.80, 158.55, 162.60.
HRMS (m/z): [MþH]þ calcd for C30H26F3N6O: 543.2120; found:
543.2136. Anal. Calcd for C30H25F3N6O: C, 66.41; H, 4.64; N, 15.49;
found C, 66.50; H, 4.86; N, 15.65.
4.1.7. 2-[5-(4-Methylphenyl)-3-{4-[5-(trifluoromethyl)pyridin-2-
yl]piperazine-1-carbonyl}-1H-pyrazol-1-yl]quinoline (4e)
Prepared from 3 (1.2 mmol) and 1-[5-(trifluoromethyl)pyridin-
2-yl]piperazine (1.3 mmol) using the method A. Flash chromatog-
raphy hexane:EtOAc; yield 72%; Mp 217 C. IR (ATR): 1633 cm1. 1H
NMR (CDCl3): d 2.37 (3H, s), 3.79 (4H, m), 3.97 (2H, bt), 4.32 (2H, bt),
6.67 (1H, d, J¼ 9.2 Hz), 6.97 (1H, s), 7.12 (2H, d, J¼ 8.0 Hz), 7.24 (2H,
d, J ¼ 8.0 Hz), 7.55e7.59 (1H, m), 7.62 (1H, d, J ¼ 8.8 Hz), 7.65e7.72
(2H, m), 7.80e7.86 (2H, m), 8.23 (1H, d, J ¼ 8.4 Hz), 8.42 (1H, s). 13C
NMR (CDCl3): d 21.30, 42.20, 44.49, 45.11, 46.58, 105.64, 111.30,
115.67 (2JCeF¼ 33Hz),117.08,124.50 (1JCeF¼ 268 Hz) 127.09,127.24,
127.47, 128.87, 128.91, 129.14, 130.32, 134.64, (3JCeF: 3 Hz), 138.53,
138.64, 145.19, 145.77 (3JCeF ¼ 5 Hz), 146.37, 147.97, 150.78, 160.17,
162.63. HRMS (m/z): [MþH]þ calcd for C30H26F3N6O: 543.2120;found: 543.2133. Anal. Calcd for C30H25F3N6O: C, 66.41; H, 4.64; N,




Prepared from 3 (1.2 mmol) and 1-[3-chloro-5-(trifluoromethyl)
pyridin-2-yl]piperazine (1.3 mmol) using the method A. Flash
chromatography hexane:EtOAc; yield 82%; Mp 154 C. IR (ATR):
1628 cm1. 1H NMR (CDCl3): d 2.37 (3H, s), 3.59e3.64 (4H, m), 4.00
(2H, bt), 4.33 (2H, bt), 6.96 (1H, s), 7.12 (2H, d, J ¼ 8.0 Hz), 7.24 (2H,
d, J ¼ 7.6 Hz), 7.55e7.58 (1H, m), 7.63 (1H, d, J ¼ 8.8 Hz), 7.68e7.72
(1H, m), 7.79e7.85 (3H, m), 8.23 (1H, d, J ¼ 8.8 Hz), 8.41 (1H, s). 13C
NMR (CDCl3): d 21.30, 42.34, 46.93, 48.53, 49.14, 111.23, 117.12,
120.99, 123.20 (1JCeF ¼ 270 Hz), 127.04, 127.37 (2JCeF ¼ 29 Hz),
127.46, 128.85, 128.91, 129.15, 130.28, 136.08, 138.48, 138.62, 143.03
(3JCeF ¼ 4 Hz), 145.15, 146.37, 148.04, 150.81, 159.64, 162.68. HRMS
(m/z): [MþH]þ calcd for C30H25ClF3N6O: 577.1730; found: 577.1757.
Anal. Calcd for C30H24ClF3N6O: C, 62.45; H, 4.19; N, 14.57; found C,
62.59; H, 4.30; N, 14.73.
4.1.9. 2-{4-[5-(4-Methylphenyl)-1-(quinolin-2-yl)-1H-pyrazole-3-
carbonyl]piperazine-1-yl}pyridine-3-carbonitrile (4g)
Prepared from 3 (1.2 mmol) and 2-(piperazin-1-yl)pyridine-3-
carbonitrile (1.3 mmol) using method A. Flash chromatography
CH2Cl2:EtOAc; yield 82%; Mp 241 C. IR (ATR): 1635 cm1. 1H NMR
(CDCl3): d 2.37 (3H, s), 3.81e3.85 (4H, m), 4.01 (2H, bt), 4.36 (2H,
bt), 6.82 (1H, dd, J ¼ 7.6 and 4.8 Hz), 6.97 (1H, s), 7.12 (2H, d,
J ¼ 8.0 Hz), 7.24 (2H, d, J ¼ 8.4 Hz), 7.54e7.58 (1H, m), 7.65 (1H, d,
J ¼ 8.4 Hz), 7.69e7.71 (1H, m), 7.78e7.85 (3H, m), 8.23 (1H, d,
J ¼ 8.4 Hz), 8.38 (1H, dd, J ¼ 4.8 and 2.0 Hz). 13C NMR (CDCl3):
d 21.30, 42.38, 46.84, 47.75, 48.82, 95.38, 111.34, 114.59, 117.06,
117.85, 127.02, 127.24, 127.46, 127.55, 128.84, 128.93, 129.16, 130.25,
138.45, 138.65, 143.82, 145.15, 146.35, 147.98, 150.79, 151.88, 160.63,
162.63. HRMS (m/z): [MþH]þ calcd for C30H26N7O: 500.2199;
found: 500.2198. Anal. Calcd for C30H25N7O: C, 72.13; H, 5.04; N,
19.63; found C, 71.94; H, 5.30; N, 19.22.
4.1.10. 2-{3-[4-(3,5-Dichloropyridin-4-yl)piperazine-1-carbonyl]-
5-(4-methylphenyl)-1H-pyrazol-1-yl}quinoline (4h)
Prepared from 3 (1.2 mmol) and 1-[3,5-dichloropyridin-4-yl]
piperazine (1.3 mmol) using method A. Flash chromatography
CH2Cl2:EtOAc; yield 72%; Mp 217 C. IR (ATR): 1614 cm1. 1H NMR
(CDCl3): d 2.36 (3H, s), 3.42e3.49 (4H, m), 4.00 (2H, bt), 4.31 (2H,
bt), 6.96 (1H, s), 7.12 (2H, d, J ¼ 8.4 Hz), 7.23 (2H, d, J ¼ 8.0 Hz),
7.55e7.58 (1H, m), 7.61 (1H, d, J ¼ 8.4 Hz), 7.67e7.72 (1H, m),
7.80e7.85 (2H, m), 8.22 (1H, d, J ¼ 8.8 Hz), 8.37 (2H, s). 13C NMR
(CDCl3): d 21.31, 43.29, 48.02, 50.04, 50.68, 111.16, 117.17, 127.07,
127.24, 127.46, 127.47, 128.63, 128.87, 128.91, 129.16, 130.29, 138.51,
138.63, 145.17, 146.38, 148.05, 149.23, 150.80, 150.96, 162.79. HRMS
(m/z): [MþH]þ calcd for C29H25Cl2N6O: 543.1467; found: 543.1459.
Anal. Calcd for C29H24Cl2N6O: C, 64.09; H, 4.45; N, 15.46; found C,
64.31; H, 4.57; N, 15.67.
4.1.11. 5-(4-Methylphenyl)-N-(pyridin-4-yl)-1-(quinolin-2-yl)-1H-
pyrazole-3-carboxamide (4i)
Prepared from 3 (1.2 mmol) and pyridin-4-amine (1.3 mmol)
using method A. Flash chromatography CH2Cl2:EtOAc; yield 78%;
Mp 184 C. IR (ATR): 1701 cm1. 1H NMR (CDCl3): d 2.36 (3H, s), 7.13
(2H, d, J ¼ 8.0 Hz), 7.17 (1H, s), 7.20 (2H, d, J ¼ 8.4 Hz), 7.43 (1H, d,
J¼ 8.4 Hz), 7.61e7.65 (1H, m), 7.69e7.71 (2H, m), 7.76e7.80 (1H, m),
7.88 (1H, d, J ¼ 8.0 Hz), 8.00 (1H, d, J ¼ 8.8 Hz), 8.23 (1H, d,
J ¼ 8.4 Hz), 8.55 (2H, d, J ¼ 6.4 Hz), 9.05 (1H, s). 13C NMR (CDCl3):
d 21.31, 109.12, 113.62, 117.55, 126.76, 127.47, 127.59, 128.81, 129.19,
129.30, 130.69, 138.82, 139.09, 144.68, 146.67, 146.78, 147.28, 150.37,
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406.1668; found: 406.1667. Anal. Calcd for C25H19N5O: C, 74.06; H,
4.72; N, 17.27; found C, 74.30; H, 5.00; N, 17.39.
4.1.12. N-(2-Chloropyridin-4-yl)-5-(4-methylphenyl)-1-(quinolin-
2-yl)-1H-pyrazol-3-carboxamide (4j)
Prepared from 3 (1.2 mmol) and 2-chloropyridin-4-amine
(1.3 mmol) using method B. Flash chromatography hexane:EtOAc;
yield 63%; Mp 190 C. IR (ATR): 1698 cm1. 1H NMR (CDCl3): d 2.35
(3H, s), 7.12 (2H, d, J ¼ 8.8 Hz), 7.15 (1H, s), 7.19 (2H, d, J ¼ 8.4 Hz),
7.41 (1H, d, J ¼ 9.2 Hz), 7.55 (1H, dd, J ¼ 5.2 and 2.0 Hz), 7.60e7.64
(1H, m), 7.75e7.79 (1H, m), 7.82 (1H, d, J ¼ 2.0 Hz), 7.88 (1H, d,
J ¼ 8.0 Hz), 7.99 (1H, d, J¼ 8.8 Hz), 8.22 (1H, d, J¼ 8.4 Hz), 8.29 (1H,
d, J ¼ 5.2 Hz), 9.07 (1H, s). 13C NMR (CDCl3): d 21.34, 109.14, 112.51,
113.48, 117.53, 126.58, 127.49, 127.60, 127.67, 128.80, 129.25, 129.28,
130.76, 138.87, 139.22, 146.67, 146.80, 146.88, 150.25, 150.27, 152.50,
159.99. HRMS (m/z): [MþH]þ calcd for C25H19ClN5O: 440.1274;
found: 440.1278. Anal. Calcd for C25H18ClN5O: C, 68.26; H, 4.12; N,
15.92; found C, 68.51; H, 4.31; N, 15.98.
4.1.13. N-(3-Bromopyridin-4-yl)-5-(4-methylphenyl)-1-(quinolin-
2-yl)-1H-pyrazol-3-carboxamide (4k)
Prepared from 3 (1.2 mmol) and 3-bromopyridin-4-amine
(1.3 mmol) using method B. Flash chromatography hexane:EtOAc;
yield 38%; Mp 228 C. IR (ATR): 1703 cm1. 1H NMR (CDCl3): d 2.37
(3H, s), 7.12 (2H, d, J ¼ 8.4 Hz), 7.15 (1H, s), 7.23 (2H, d, J ¼ 8.0 Hz),
7.57e7.61 (1H, m), 7.69e7.73 (2H, m), 7.81 (1H, d, J ¼ 8.0 Hz), 7.87
(1H, d, J ¼ 8.0 Hz), 8.29 (1H, d, J ¼ 8.4 Hz), 8.48 (1H, d, J ¼ 5.6 Hz),
8.60 (1H, d, J ¼ 5.6 Hz), 8.68 (1H, s), 9.74 (1H, s). 13C NMR (CDCl3):
d 21.32, 109.35, 110.75, 114.63, 116.80, 127.17, 127.36, 127.43, 127.52,
128.93, 129.21, 130.50, 138.86, 138.95, 142.54, 146.30, 146.79, 147.04,
149.71, 150.45, 151.76, 160.07. HRMS (m/z): [MþH]þ calcd for
C25H19BrN5O: 484.0773; found: 484.0777. Anal. Calcd for




Prepared from 3 (1.2 mmol) and 3,5-dibromopyridin-2-amine
(1.3 mmol) using method B. Flash chromatography hexane:EtOAc;
yield 21%; Mp 208 C. IR (ATR): 1714 cm1. 1H NMR (CDCl3): d 2.37
(3H, s), 7.12 (2H, d, J ¼ 8.0 Hz), 7.19 (1H, s), 7.23 (2H, d, J ¼ 7.6 Hz),
7.59e7.61 (1H, m), 7.66 (1H, d, J ¼ 8.8 Hz), 7.71e7.75 (1H, m),
7.85e7.88 (2H, m), 8.06 (1H, d, J ¼ 2.0 Hz), 8.27 (1H, d, J ¼ 8.4 Hz),
8.54 (1H, d, J¼ 2.0 Hz), 9.67 (1H, s). 13C NMR (CDCl3): d 21.31,109.56,
111.45, 114.85, 117.03, 127.22, 127.32, 127.39, 127.50, 128.91, 128.94,
129.24, 130.46, 138.76, 138.82, 143.00, 146.38, 146.82, 147.27, 147.37,
148.34, 150.55, 158.50. HRMS (m/z): [MþH]þ calcd for
C25H18Br2N5O: 561.9878; found: 561.9885. Anal. Calcd for




Prepared from 3 (1.2 mmol) and 2,6-dichloropyridin-3-amine
(1.3 mmol) using method B. Flash chromatography CH2Cl2(100%);
yield 35%; Mp 247 C. IR (ATR): 1691 cm1. 1H NMR (CDCl3): d 2.37
(3H, s), 7.12 (2H, d, J ¼ 8.0 Hz), 7.14 (1H, s), 7.24 (2H, d, J ¼ 7.6 Hz),
7.34 (1H, d, J ¼ 8.8 Hz), 7.58e7.62 (1H, m), 7.68 (1H, d, J ¼ 8.8 Hz),
7.70e7.74 (1H, m), 7.82e7.88 (2H, m), 8.28 (1H, d, J ¼ 8.8 Hz), 8.95
(1H, d, J ¼ 8.8 Hz), 9.48 (1H, s) 13C NMR (CDCl3): d 21.32, 109.18,
116.93, 123.74, 127.13, 127.40, 127.44, 127.53, 128.91, 128.97, 129.22,
130.51, 130.92, 131.24, 138.60, 138.87, 138.94, 143.22, 146.35, 146.74,
146.98, 150.42, 150.99. HRMS (m/z): [MþH]þ calcd for




Prepared from 3 (1.2 mmol) and 2-methoxypyridin-3-amine
(1.3 mmol) using method A. Flash chromatography hexane:EtOAc;
yield 75%; Mp 193 C. IR (ATR): 1673 cm1. 1H NMR (CDCl3): d 2.36
(3H, s), 4.06 (3H, s), 6.95 (1H, dd, J ¼ 8.0 and 4.8 Hz), 7.12 (2H, d,
J ¼ 8.0 Hz), 7.14 (1H, s), 7.23 (2H, d, J ¼ 8.0 Hz), 7.58e7.63 (2H, m),
7.72e7.76 (1H, m), 7.86e7.91 (3H, m), 8.27 (1H, d, J ¼ 8.0 Hz), 8.78
(1H, dd, J ¼ 8.0 and 2.0 Hz), 9.32 (1H, s). 13C NMR (CDCl3): d 21.31,
53.75, 109.14, 117.24, 117.38, 122.76, 126.60, 127.27, 127.30, 127.40,
127.51, 128.88, 128.97, 129.26, 130.44, 138.72, 138.75, 140.23, 146.47,
146.52, 147.82, 150.65, 153.43, 160.13. HRMS (m/z): [MþH]þ calcd
for C26H22N5O2: 436.1774; found: 436.1775. Anal. Calcd for




Prepared from 3 (1.2 mmol) and pyridin-3-ylmethanamine
(1.3 mmol) using method A. Flash chromatography CH2Cl2:MeOH;
yield 81%; Mp 134 C. IR (ATR): 1628 cm1. 1H NMR (CDCl3): d 2.35
(3H, s), 4.69 (2H, d, J ¼ 6.0 Hz), 7.10e7.12 (3H, m), 7.19 (2H, d,
J¼ 7.6 Hz), 7.27e7.29 (1H, m), 7.42 (1H, d, J¼ 9.2 Hz), 7.47e7.50 (1H,
bt), 7.57e7.60 (1H, m), 7.71e7.76 (2H, m), 7.84 (1H, d, J ¼ 8.4 Hz),
7.92 (1H, d, J ¼ 8.8 Hz), 8.17 (1H, d, J ¼ 8.8 Hz), 8.54 (1H, dd,
J ¼ 5.0 Hz and J ¼ 1.4 Hz), 8.63 (1H, d, J ¼ 2.4 Hz). 13C NMR (CDCl3):
d 21.29, 40.68, 109.01, 117.46, 123.55, 127.14, 127.33, 127.48, 128.81,
129.06, 129.28, 130.47, 133.94, 135.74, 138.63, 138.79, 146.16, 146.61,
147.54, 148.95, 149.36, 150.55, 161.81. HRMS (m/z): [MþH]þ calcd
for C26H22N5O: 420.1824; found: 420.1818. Anal. Calcd for
C26H21N5O: C, 74.44; H, 5.05; N, 16.70; found C, 74.49; H, 4.73; N,
16.64.
4.2. Biological studies
Cell culture: Cell lines were obtained from the following sources
and validated by STR analysis: Mahlavu [27], Huh7 (JCRB
JCRB0403), HCT116 (ATCC CCL-247), MCF7 (ATCC HTB22). Cell lines
were grown in Dulbecco's modified Eagle's medium (DMEM) sup-
plemented with 10% fetal calf serum (FCS) and 50 mg/ml penicillin/
streptomycin. Each cell line was maintained in a humidified incu-
bator at 37 C supplied with 5% CO2.
4.2.1. Sulforhodamine B (SRB) assay for cytotoxicity screening
Human liver (Huh7), colon (HCT116) and breast (MCF7) cancer
cells were inoculated (2000e3000 cells/well in 200 mL) in 96-well
plates. The next day, the media were refreshed and the compounds
dissolved in DMSOwere applied in increasing concentrations of the
compounds (2.5e40 mM) and incubated. DMSO-only treated cells
were used as negative controls (for 40 mMcompound concentration
0.2% DMSO, for 20 mM compound 0.1% DMSO, for 10 mM of com-
pound 0.05% DMSO, for 5 mM compound 0.025% DMSO, for 2.5 mM
of compound 0.012% DMSO was used as vehicle control). Campto-
thecin was used as positive control. At the 72 nd hour of treatment
with compounds 4aeo and the other drugs, the cancer cells were
fixed with 100 mL of 10% (w/v) trichloroacetic acid (TCA) and kept
at þ4 C in the dark for one hour. TCA fixation was terminated by
washing the wells with ddH2O five times. Air-dried plates were
stained with 0.4% sulforhodamine B (SRB) dissolved in 1% acetic
acid solution for 10 min in the dark and at room temperature. The
protein-bound and dried SRB dye was then solubilized with 10 mM
Tris-Base pH 8. The absorbance values were obtained at 515 nm in a
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wells, which were used as controls in serial dilutions. In all ex-
periments, a linear response was observed, with serial dilutions of
the compounds and the drugs; R2  0.9. Data for anticancer activity
were analyzed by one-way ANOVA and expressed as means of ±SD.4.2.2. Hoechst stain
Human liver cancer cells (Huh7) were inoculated on coverslips
in 6-well plates for 24 h. Then the cells were treated with IC50
concentrations of the compounds for 72 h. To determine nuclear
condensation by Hoescht 33258 (SigmaeAldrich) staining, cells
were fixed with 1 ml of cold methanol for 10 min after being
washed twice with ice cold 1 PBS. Then the samples were incu-
batedwith 3 mg/mL of Hoescht for 5 min in darkness. The coverslips
were then rinsed with distilled water, mounted on glass micro-
scopic slides using 50% glycerol, and examined under fluorescent
microscopy (40).4.2.3. Western blotting
Human liver cancer cells (Huh7) cells were treated with the
compounds or DMSO control for 72 h. Equal amounts of cell lysates
were solubilized with 1 loading dye, SRA (or DTT). (Protein con-
centration of lysates was determined by the Bradford assay.) Then
the lysates were denatured for 10 min in 100 C. 30 ng of proteins
were loaded to the gels. NuPAGE NOVEX pre-cast gel system was
used for throughout thewestern blot analysis procedures according
to the manufacturer's protocol. MES running buffer was used.
Following electrophoresis, proteins were transferred to nitrocellu-
lose membrane (30 V, 90 min) followed by incubation in blocking
solution (5% BSA in 1 TBS-T (0.1% tween)) for one hour at room
temperature. LC3B (L7543, Sigma Aldrich) primary antibody was
used in a ratio of 1:2000 in 5% milk-TBS-T, 2 h at room temperature.
Secondary antibody, anti-rabbit (Sigma, A6154) was applied in
1:5000 ratio in 5% BSA-TBS-T (0.1%) for one hour at room temper-
ature. Actin (Sigma, A5441) primary antibody for equal loading
analysis was used in 1:5000 dilution in 5% milk-powder in TBST
(0.1%) for 1 h at room temperature. For visualization of the results,
chemiluminescence was performed with ECLþ kit according to the
manufacturer's protocol. The chemiluminescence light was
captured on X-ray film. ImageJ software was used for quantification
of band intensity. Quantification results were obtained by
normalizing to actin equal loading bands and DMSO controls.4.2.4. Fluorescence-activated cell sorting analysis (FACS)
Human hepatocellular carcinoma cells (Huh7) were seeded into
100-mm culture dishes (150,000e300,000 cells/dish). After 24 h
incubation, cells were treated with IC50 concentrations of the
selected compounds for 48 h. Then cells were trypsinized and
collected as cell pellets. Samples were fixed in ice-cold 70% ethanol
and stored at 20 C. Before the analysis, the samples were stained
with MUSE Cell cycle Reagent (contains propidium iodide solution)
according to the manufacturer's protocol. Cell cycle analysis was
conducted with MUSE Cell Cycle Analyzer.Acknowledgment
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